EN DE
Watch Pfizer Inc for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Pfizer Inc (PFE) fair value: what the stock is really worth

As of Nov 5, 2026: fair value (intrinsic value) of Pfizer Inc stock $24.87, price $29.88, that is 16.8% below the price, quality 61 out of 100. Rating: overvalued. Calculated from audited financials with 23 of our 26 valuation models and 37 quality factors, updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare US

PI Pfizer Inc logo Broad data Nov 4, 2026

Pfizer Inc

PFE · US
Solid, but expensive

Our calculation puts a fair price 17% below what the stock costs today.

Quality 61/100
Generates free cash flow
Broad data
Mixed Growth (revenue 5y +8.5 %/yr in USD)
Thin margins · 6.8% net margin (TTM)
Moderate debt
5.8% dividend yield · Payout strained
Mixed vs. peers (6/14)
Moderate moat 54/100
Insiders bought $3.0M (6M) · sold $134,661
Fair value $24.87 · Overvalued (−16.8%)
Negative coverage

Risks from the AI analysis

🚩Patent expiries draw generic rivals🚩Acquisition debt raises refinancing needs
Watch Pfizer Inc for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

$47.42 $19.46 Fair Value $24.87 Aug 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 4, 2026.

How to read this chart

60‑month range $19.46 – $47.42 · fair‑value band $14.50 – $37.49 · the $29.88 price screens above the $24.87 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 4, 2026.

Follow Pfizer in your weekly email

Every Wednesday you see whether Pfizer is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. It operates in three segments: Biopharma, PC1, and Pfizer Ignite.

Show moreShow less

The company offers internal medicine products, including cardiovascular metabolic diseases products under the Eliquis brand; migraine products under the Nurtec ODT/Vydura and Zavzpret brand; vaccines under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and Paxlovid for the treatment of COVID-19. It also provides inflammation and immunology products, such as Xeljanz, Enbrel, Cibinqo, Litfulo, Eucrisa, and Velsipity; rare disease products for therapeutic areas comprising amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel family, Genotropin, BeneFIX, Xyntha, Somavert, Ngenla, and Hympavzi brands; and anti-infective and immunoglobulin medicines under the Zavicefta, Octagam, and Panzyga brands.

In addition, the company offers oncology products comprising ADCs, small molecules, bispecific, and other immunotherapies for the treatment of cancers, including breast cancer, genitourinary cancer, and hematologic malignancies, as well as melanoma, gastrointestinal, gynecological, and lung cancer under the Ibrance, Xtandi, Padcev, Adcetris, Inlyta, Lorbrena, Bosulif, Tukysa, Braftovi, Mektovi, Orgovyx, Elrexfio, Tivdak, and Talzenna brands.

Further, it provides biosimilars under the Inflectra brand; oncology biosimilars comprising Retacrit, Ruxience, Zirabev, Trazimera and Nivestym, and other biosimilars; and sterile injectables, such as Sulperazon, Atgam, Fragmin, Solu Medrol, Solu Cortef, and Bicillin.

The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE, as well as a strategic collaboration with Boltz, PBC to develop and deploy biomolecular AI foundation models.

Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Stock analysis

Pfizer Inc (PFE) currently trades at $29.88, while our model-based Fair Value estimate is $24.87, 17% below the price, so the stock looks overvalued today.

Show more

Valuation

Bull case: the Multiples group reads highest at a median of $29.99 per share, and 6 of the 23 models we run sit above the $29.88 price.

Bear case: the Economic Profit group reads lowest at $14.82, and 17 of the 23 models stay below the price. Data coverage for this calculation is high.

Scenario range: $14.50 (bear) to $37.49 (bull), the price of $29.88 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 61/100 (solid quality), in the Healthcare sector.

Mixed Growth: Spin-off in 2020: revenue and profit before it include the divested business. Growth is measured afresh from 2020.

Pfizer Inc reported revenue of $62.6B in FY2025 versus $81.3B in FY2021, a compound −6.3%/yr. Reported net income was $7.8B in FY2025, compounding −23.0%/yr from FY2021.

Key figures

Market cap $170B Large · P/E ratio 40.4 · P/S ratio 2.67 · EPS (TTM) $0.7400 · Dividend yield 5.8% · Net margin 6.8% · Return on equity 5.0% · Return on assets (EBIT) 9.6%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 54 out of 100 (medium confidence).

What moves the price

The last reported earnings sit well below what analysts expect (earnings in transition, for example after write-downs or an earnings dip); whether the stock is cheap or expensive hinges on the expected recovery actually arriving. Read the fair value with that caveat.

The share trades about 3% below its 52-week high and 30% above its 52-week low, currently above its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −10% fair-value upside, at −17%, PFE screens richer than that median.

Fair Value models

Bear $14.50 Fair Value $24.87 Bull $37.49
Price $29.88 · Downside -16.8%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
FCF DCF $13.68 $26.82 $47.94 74
EPV $14.99 $19.71 $23.98 74
Residual Income $13.47 $14.82 $17.83 74
All 23 models by family
DCF Models
FCF DCF $13.68 $26.82 $47.94 74
Owner Earnings $8.00 $18.06 $34.22 70
5Y Revenue Exit $12.09 $24.58 $40.13 68
5Y EBITDA Exit $21.43 $41.45 $64.18 71
5Y P/E Exit $10.79 $22.23 $33.76 67
10Y Revenue Exit $11.70 $23.38 $38.21 62
10Y EBITDA Exit $18.55 $35.37 $56.76 64
10Y P/E Exit $11.58 $21.71 $33.31 60
Earnings-Based
Graham-Dodd $9.27 $23.81 $30.99 63
PEG = 1.0 $4.47 $6.38 $8.29 55
EPV $14.99 $19.71 $23.98 74
Dividend Discount
Gordon GGM $17.18 $36.65 $70.54 62
DDM Multi-Stage $17.18 $27.25 $39.12 64
Multiples
P/E Multiple $22.49 $29.99 $37.49 63
P/S Multiple $17.38 $23.18 $28.97 58
EV/EBIT $22.90 $34.42 $45.93 65
EV/EBITDA $28.95 $42.48 $56.01 66
EV/Revenue $11.43 $21.31 $31.19 52
Growth DCF
Growth DCF $14.50 $26.74 $45.52 73
Rev-Margin DCF $12.09 $24.74 $38.58 68
Economic Profit
Residual Income $13.47 $14.82 $17.83 74
ROIC Compounder $14.99 $21.82 $30.68 69
Growth Earnings
Growth-Adj P/E $17.41 $24.87 $32.33 65

Open the full fair value analysis →

Quality Score breakdown

Overall quality 61/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 37
How much profit the company makes from its sales and capital
Quality Growth 43
Are margins and returns getting better?
Cashflow 68
Do the profits arrive as real cash?
Financial strength 44
Debt, balance sheet and risk of trouble
Investment 93
Does it invest with discipline instead of growing at any price?
Low Volatility 93
How calm the share price moves, does not count
Price momentum 61
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 78
Distance to the 52-week high, does not count
New shares 81
Buys back shares or issues new ones?

Open the full quality analysis →

Insider trades

In the last 6 months, 3 officers or directors bought shares worth $3.0M, most recently on Aug 12, 2026. Over the same period, one person sold shares worth $134,661. Buying cluster

  • BuyAlbert BourlaChairman & CEO, Director38,000 shares at $26.34$1.0MAug 12, 2026
  • SaleJennifer B. DamicoSVP & Controller2× since Jun 9, 2026: 5,278 shares, avg. $25.51$134,661Aug 5, 2026
  • BuyMortimer J BuckleyDirector37,632 shares at $25.52$960,369Aug 5, 2026
  • BuyRonald E BlaylockDirector39,231 shares at $25.46$998,821Aug 5, 2026

Sales are often planned (taxes, diversification, 10b5-1 plans). Purchases with their own money are seen as the stronger sign. For information only: not part of the quality score or Fair Value.

Source: SEC Form 4, as of Nov 5, 2026. All filings at the SEC ↗

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 55/100
Spin-off in 2020: revenue and profit before it include the divested business. Growth is measured afresh from 2020.
Revenue growth 1 year
−1.6%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−14.6%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+8.5%
Start year 2020 (pandemic)
What shareholders gained per year (last 5 years) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate.
−7.1%
Earnings growth per share plus dividend.
Earnings per share, growth per year−12.9%
Dividend (yield on the price)5.8%
Per share before 2020divided by the spin-off factor 1.054
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.−12.9% vs −13.1%, steady
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.22% → 25%
Pace: the 5-year rate starts in 2020 (pandemic)
⚠ Revenue per share shrinking 11.3%/yr over ~10Y (margins eroding too) ⓘStructural-decline marker: revenue PER SHARE has fallen over the last decade (robust median trend, not a single year). Backtested across 2005 to 2017, such businesses trailed the market by about 2.5 percentage points per year. Display only: it does not change the fair value or the quality score.

Growth Forecast

A lot of optimism in the price
The price assumes about as much growth as the company has delivered so far and more than analysts expect.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+8.5%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect ⓘAnalysts publish sales forecasts for the next two fiscal years. For the years after that, growth slows evenly to 2 % a year by year ten (2 % is the long-run rate our models use). Projected years are marked as such.
−2.3%
Yearly sales growth analysts expect, extended to five years.
After inflation (USA: IMF forecast 2.4% a year to 2030, 3.1% from 2016 to 2025) that is about +6.0% a year for the price and −4.5% for the forecasts.
Forecast 2026 (sales)−0.6%
Forecast 2027 (sales)−3.8%
Projected 2028 (sales)−3.0%
Projected 2029 (sales)−2.3%
Projected 2030 (sales)−1.6%

PFE screens overvalued: fair value 17% below the price. Compare with Eli Lilly and Company →

Recent news

News mood ⓘNews mood, the average tone of recent news (97 articles), rated against how stocks are usually covered. 🚀 Hype = unusually upbeat · 🙂 Positive = above average · 😐 Neutral = typical · 🙁 Negative = below average · 😨 Very negative = unusually downbeat. It reflects the tone of coverage, not our valuation. Negative
Recent news coverage is more negative than average.
Note from the team Nov 5, 2026
AI conclusion: Pfizer shows strength through operational growth in non-COVID products and cost savings, while its main weakness remains limited differentiation in innovation and below-average returns amid patent expirations on legacy franchises.
Main risk: Expiring patents on products such as Eliquis and Prevnar could allow generic and biosimilar makers to enter with lower-priced versions and erode Pfizer's revenues and margins on those drugs.
Bull case: Pfizer could accelerate its pipeline in oncology and obesity through partnerships and acquisitions to replace lost exclusivity revenues with new differentiated products.
Bear case: If multiple key patents expire without sufficient replacements, generic competition could sharply reduce revenues from major products and strain the company's ability to service its debt load.
Pfizer raised its full-year 2026 outlook after non-COVID products grew seven percent operationally and cost savings gained momentum. The CEO is applying the Viagra playbook to obesity with ten phase III trials planned for next year, even as established franchises face patent expirations and competition. Will the obesity push expand the business faster than legacy erosion subtracts or merely offset the declines?
Join the discussion →

Compare Pfizer Inc with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - General · 74 stocks

Beats the industry median on 6/14 measures
A mixed picture versus its industry peers.
Valuation
Quality Score 61 · Above median
Fair Value upside −16.8% · Below median
Profitability
Return on equity (12 months) 5.0% · Below median
Return on assets 3.7% · Below median
Net margin (12 months) 6.8% · Below median
Operating margin (12 months) 27.9% · Above median
Growth and dividend
Revenue growth (quarter YoY) 2.6% · Below median
Dividend yield (12 months) 5.8% · Top 25%
Balance sheet
Debt / equity 0.70× · Highest 25%

Valuation Multiplesvs Drug Manufacturers - General median · lower = cheaper

P/E (12 months) 40.4× · Priciest 25%
P/B 1.97× · book value is mostly goodwill ⓘGoodwill and other intangible assets are larger than the equity. The book value mainly reflects prices paid for past acquisitions, so we do not rank this P/B against the peer group.
P/S (12 months) 2.67× · Cheaper than median
Price / free cash flow (fiscal year) 18.8× · Cheaper than median
EV/EBITDA 9.1× · Cheaper than median
PEG 14.05× · Priciest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)11 · sector 20
FUTURE (revenue growth)13 · sector 34
PAST (return on equity)20 · sector 41
HEALTH (low debt)65 · sector 93
DIVIDEND (yield)100 · sector 38

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Drug Manufacturers - General stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Sanofi SNY $46.91 $70.49 +50% vs PFE
Bristol-Myers Squibb Company BMY $63.13 $75.91 +20% vs PFE
Gilead Sciences, Inc GILD $167.57 $191.93 +15% vs PFE
Amgen Inc AMGN $460.28 $507.39 +10% vs PFE
AbbVie Inc ABBV $288.24 $259.62 −10% vs PFE
Novartis AG NOVN CHF 134.12 CHF 119.58 −11% vs PFE
Merck & Co MRK $146.94 $129.26 −12% vs PFE
Roche Holding RO CHF 399.00 CHF 326.56 −18% vs PFE
Johnson & Johnson, JNJ $272.32 $168.85 −38% vs PFE
Eli Lilly and Company LLY $1,365 $749.92 −45% vs PFE

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Evidence & backtest34 years, failed companies included Financial calculatorsDCF, Graham, PEG and more
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Pfizer Inc: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Pfizer Inc Fair Value". https://www.fairvalue-calculator.com/stock/PFE

Frequently asked questions

Is Pfizer Inc (PFE) overvalued or undervalued?
As of Nov 4, 2026, our model estimates a fair value of $24.87 versus a price of $29.88, about 17% lower (overvalued).
What is the fair value of PFE?
Our model-based fair value for Pfizer Inc is $24.87 (as of Nov 4, 2026), built from audited fundamentals. The current price: $29.88.
What is the quality score of PFE?
Pfizer Inc has a Quality Score of 61/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Pfizer Inc (PFE)?
Our model-based price target is the fair value of $24.87 (as of Nov 4, 2026) from 23 valuation models. Cautious scenario $14.50, optimistic scenario $37.49. It is a calculation from audited fundamentals, not an analyst target.
What is the Pfizer Inc stock forecast for 2026?
Our models put fair value at $24.87, about 17% lower versus a price of $29.88 (overvalued). Cautious scenario $14.50, optimistic scenario $37.49. The calculation is refreshed regularly with new filings.
What is the revenue of Pfizer Inc (PFE)?
Pfizer Inc reported trailing-twelve-month revenue of about $63.7B (latest available figure, as of Nov 4, 2026).
Does Pfizer Inc pay a dividend?
Pfizer Inc currently shows a dividend yield of 5.76% relative to its recent price (as of Nov 4, 2026).
What growth is priced into Pfizer Inc (PFE)?
For today's price to be fair in a discounted-cash-flow model, Pfizer Inc would have to grow free cash flow by +8.5 % per year for five years (discount rate 8.1 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +8.5 % per year. As of Nov 4, 2026.
What discount rate (WACC) does the fair value of PFE use?
Our models discount Pfizer Inc at 8.1 %: a base by market capitalisation (large), damped by beta 0.30, country premium for USA. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Pfizer Inc that is +8.5 % per year a year over ten years, using the same discount rate (8.1 %) and the same formula as our fair value.
How much growth has Pfizer Inc (PFE) delivered so far?
Over the past 5 years revenue at Pfizer Inc grew +8.5 % a year. The price currently implies +8.5 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Pfizer Inc (PFE) growing?
The median revenue growth in the sector is +6.2 % a year. That is the yardstick for the growth priced into Pfizer Inc (+8.5 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Pfizer Inc (PFE)?
The free-cash-flow yield on the price is 5.33 %: that much free cash flow Pfizer Inc produces per unit of market value. When it exceeds the discount rate of our models (8.1 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Pfizer Inc (PFE)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Pfizer Inc it is $24.87 per share (as of Nov 4, 2026), against a price of $29.88. It is the blended result of 23 valuation models (cash flow, earnings, asset, dividend).
Is Pfizer Inc stock overvalued or undervalued in 2026?
As of Nov 4, 2026, PFE trades above its calculated fair value: price $29.88, fair value $24.87, a gap of about −17% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of PFE?
No. The price is what the market pays today ($29.88); the fair value is what the company's own numbers justify ($24.87). For Pfizer Inc the two are $5.01 per share apart. That gap is exactly why we show both numbers side by side.
How much is Pfizer Inc worth?
The market values Pfizer Inc at about $170B (market capitalisation, as of Nov 4, 2026). Per share that is $29.88; our models calculate a fair value of $24.87 per share.
What do the bullish and bearish scenarios say about PFE?
Our models span a range for Pfizer Inc: cautious scenario $14.50, base $24.87, optimistic $37.49 per share (as of Nov 4, 2026, price $29.88). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of PFE?
Pfizer Inc trades at a price-to-earnings ratio of 40.4 (as of Nov 4, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of $24.87 is built from several models across several years. Median P/E at fiscal year-end, 6 fiscal years (2020 to 2025), reported earnings: 18.5. Other multiples: PEG 14.1, P/B 2.0, P/S 2.7, EV/EBITDA 9.1.
What is the PEG ratio of PFE?
The PEG ratio of Pfizer Inc is 14.05 (P/E divided by earnings growth, as of Nov 4, 2026). That is above 1, so the growth is already paid for in the price.
How solid is the balance sheet of Pfizer Inc (PFE)?
Balance-sheet figures for Pfizer Inc (as of Nov 4, 2026): return on equity 5.0%, debt of 0.70 per unit of equity. They feed the Quality Score of 61/100, which measures business quality independently of the share price.
How far is PFE from its 52-week high?
Pfizer Inc trades at $29.88, about 3% below its 52-week high of $30.79 and 30% above the low of $23.00 (as of Nov 5, 2026). Distance from the high says nothing about value: that is what the fair value of $24.87 is for.
Which stocks are comparable to Pfizer Inc?
From the same area (Healthcare) we also value Eli Lilly and Company, Johnson & Johnson,, AbbVie Inc, Roche Holding, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Pfizer Inc stock attractive at the current price?
The data as of Nov 4, 2026: price $29.88, calculated fair value $24.87 (−17%), Quality Score 61/100, from 23 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of PFE calculated?
We run Pfizer Inc through 23 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of $24.87, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 15.5% above its aggregate fair value. Pfizer Inc itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Pfizer Inc (PFE)?
The closing price on Nov 5, 2026 was $29.88. Our model-based fair value is $24.87, about 17% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Pfizer Inc right now?
Solid but not exceptional quality (61/100) and above fair value, neither a clear bargain nor a standout compounder. A fairly wide model range ($14.50 to $37.49) leaves room in how you read the outcome.

Key figures of Pfizer Inc

How large is the market capitalisation of Pfizer Inc (PFE)?
The market capitalisation of Pfizer Inc is $170B. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Pfizer Inc (PFE)?
The price-to-sales ratio of Pfizer Inc is 2.67 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Pfizer Inc (PFE)?
Earnings per share at Pfizer Inc are $0.7400 (price ÷ EPS = P/E 40.4). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Pfizer Inc (PFE)?
The dividend yield of Pfizer Inc is 5.8%. Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Pfizer Inc (PFE)?
The net margin of Pfizer Inc is 6.8% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Pfizer Inc (PFE)?
The return on equity (ROE) of Pfizer Inc is 5.0% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Pfizer Inc (PFE)?
On an EBIT basis the return on assets of Pfizer Inc is 9.6% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Pfizer Inc (PFE)?
The operating margin of Pfizer Inc is 27.9% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Pfizer Inc (PFE)?
Revenue at Pfizer Inc is growing +2.6% versus a year earlier (3y avg −14.6%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Pfizer Inc (PFE)?
Earnings per share at Pfizer Inc are growing −10.1% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net debt does Pfizer Inc (PFE) carry?
The net debt of Pfizer Inc is $66.3B (fiscal year 2025, ≈ 7.3 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch Pfizer Inc in the live analysis

One click puts Pfizer Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.